|
1 |
Atlas der gynäkologischen Operationen
Stuttgart : Thieme, 2026, 9. vollständig überarbeitete und erweiterte Auflage
|
Ankündigung
|
|
2 |
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
Hörner, Manuel. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2026
|
|
|
|
3 |
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study
Schneeweiss, Andreas. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
4 |
High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer – Results from a Large Real-World Claims Data Analysis in Germany
Enthalten in Geburtshilfe und Frauenheilkunde 10.09.2025
|
|
|
|
5 |
Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020
Dannehl, Dominik. - Freiburg : Universität, 2024
|
|
|
|
6 |
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
Enthalten in Geburtshilfe und Frauenheilkunde Bd. 84, 2024, Nr. 05: 459-469
|
|
|
|
7 |
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
Enthalten in Geburtshilfe und Frauenheilkunde Bd. 84, 2024, Nr. 02: 185-195
|
|
|
|
8 |
Die PRAEGNANT-Studie
Enthalten in Senologie Bd. 21, 2024, Nr. 04: 268-270
|
|
|
|
9 |
Happy Birthday, Senologie!
Enthalten in Senologie Bd. 21, 2024, Nr. 03: 159-159
|
|
|
|
10 |
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
Enthalten in Senologie Bd. 21, 2024, Nr. 02: 140-150
|
|
Administration
